It's the first halftime, nothing else to do but come chat with Yahoo Sports fantasy analysis live in real time and get up to the minute updates on what changes you need to make to your lineup.
It's the first halftime, nothing else to do but come chat with Yahoo Sports fantasy analysis live in real time and get up to the minute updates on what changes you need to make to your lineup.
Indian film superstar Rajinikanth on Thursday became the latest in a long line of big-name actors to enter politics, vowing to bring in "corruption-free" government to his home state.
FORM 8.5 (EPT/RI)PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)1. KEY INFORMATION(a) Name of exempt principal trader:Shore Capital Stockbrokers Ltd (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeNucleus Financial Group PLC (c) Name of the party to the offer with which exempt principal trader is connected:Nucleus Financial Group PLC (d) Date dealing undertaken:02 December 2020 (e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?No 2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER(a) Purchases and salesClass of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid/receivedLowest price per unit paid/received OrdinaryPurchases66,608183p170.75p OrdinarySales87,656190p180p (b) Derivatives transactions (other than options)Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit (c) Options transactions in respect of existing securities(i) Writing, selling, purchasing or varyingClass of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit (ii) ExercisingClass of relevant securityProduct description e.g. call optionNumber of securitiesExercise price per unit (d) Other dealings (including subscribing for new securities)Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable) The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.3. OTHER INFORMATION(a) Indemnity and other dealing arrangementsDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state “none” None (b) Agreements, arrangements or understandings relating to options or derivativesDetails of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” None Date of disclosure:03/12/2020 Contact name:Molly Adkin Telephone number:020 7647 8154 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at firstname.lastname@example.org. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
Investors are all-in on this pot stock's plans to expand outside of Canada. Should you give its shares a try as well?
The global tin market is expected to narrow its deficit to 2,700 tonnes next year from a 5,200 tonne deficit in 2020, the International Tin Association said on Thursday. Demand for refined tin is due to rise by about 6% to 361,500 tonnes next year, James Willoughby, manager of market intelligence for the association, told an online seminar.
2021 March 3 Annual Report for 2020 March 26 Annual General Meeting 2021 May 28 Interim Report, Q1 September 1 Interim Report, Q2 November 24 Interim Report, Q3The annual and interim reports are expected to be announced at approximately 7:30 CET on the dates above.ContactInvestor Relations Jens Bak-Holder Head of Investor Relations T: +45 2128 5832 Media Relations Steffen Stoevelbaek Global Media Relations T: +45 2067 0833Attachment * 13 Announcement_03122020_Financial calendar
For long-term investors, these wild vacillations in the stock market are blessings in disguise. Since bull market rallies have erased every stock market correction, volatility is nothing more than a green light for patient investors to go shopping. Online investing app Robinhood, which is known for its commission-free trades and gifting of free shares of stock to new members, has added millions of new users in 2020.
Practically everything is going right for Moderna (NASDAQ: MRNA) these days. The biotech announced surprisingly positive efficacy results for its COVID-19 vaccine candidate mRNA-1273, and it has filed for Emergency Use Authorization (EUA) in the U.S. and approval in Europe. Moderna's shares have understandably skyrocketed.
VIRGINIA BEACH, Va., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Armada Hoffler Properties, Inc. (NYSE: AHH) will host a conference call and webcast at 4:30 p.m. EST on Monday, December 7, 2020 to discuss its joint venture to develop and build T. Rowe Price’s new 450,000 square foot global headquarters at Harbor Point. The call will include prepared remarks by senior management and a question and answer session. An accompanying presentation will be made available prior to the call through the investors page of Company’s website, ArmadaHoffler.com. To listen to the call, dial 877-407-3982 (domestic) or 201-493-6780 (international) approximately 10 minutes prior to the start time of the call. The conference call will also be available through the investors page of the Company’s website, ArmadaHoffler.com.A telephonic replay will be available shortly after the conclusion of the call through Thursday, January 7, 2021. This replay may be accessed by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and providing passcode 13713873. A replay of the webcast will also be available for 30 days beginning approximately two hours after the conclusion of the conference call.About Armada Hoffler Properties, Inc. Armada Hoffler Properties, Inc. (NYSE: AHH) is a vertically-integrated, self-managed real estate investment trust ("REIT") with four decades of experience developing, building, acquiring, and managing high-quality, institutional-grade office, retail, and multifamily properties located primarily in the Mid-Atlantic and Southeastern United States. In addition to developing and building properties for its own account, the Company also provides development and general contracting construction services to third-party clients. Founded in 1979 by Daniel A. Hoffler, the Company has elected to be taxed as a REIT for U.S. federal income tax purposes. For more information, visit ArmadaHoffler.com.Contact: Michael P. O’Hara Armada Hoffler Properties, Inc. Chief Financial Officer, Treasurer, and Secretary Email: MOHara@ArmadaHoffler.com Phone: (757) 366-6684
The Board of Control for Cricket in India will meet later this month to decide whether to add two additional teams to the big-hitting Indian Premier League.
Rail Asset Management Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Rail Asset Management Market is expected to grow from USD 9,185.New York, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Rail Asset Management Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05993382/?utm_source=GNW 34 Million in 2019 to USD 13,745.82 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.94%. Market Segmentation & Coverage: This research report categorizes the Rail Asset Management to forecast the revenues and analyze the trends in each of the following sub-markets: Based on Geography, the Rail Asset Management Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Rail Asset Management Market including Accenture PLC, Alstom SA, Assetic Pty Ltd., Capgemini SE, Cisco Systems, Inc., Cyient Ltd, Hitachi, Ltd., Huawei Technologies Co., Ltd., International Business Machines Corporation, KONUX GmbH, L&T Technology Services Limited, OXplus B.V., SAP SE, Siemens AG, Trimble Inc., Wabtec Corporation, and ZEDAS GmbH. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Rail Asset Management Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth. Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market. The report provides insights on the following pointers: 1\. Market Penetration: Provides comprehensive information on the market offered by the key players 2\. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3\. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4\. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5\. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments The report answers questions such as: 1\. What is the market size and forecast of the Global Rail Asset Management Market? 2\. What are the inhibiting factors and impact of COVID-19 shaping the Global Rail Asset Management Market during the forecast period? 3\. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Rail Asset Management Market? 4\. What is the competitive strategic window for opportunities in the Global Rail Asset Management Market? 5\. What are the technology trends and regulatory frameworks in the Global Rail Asset Management Market? 6\. What are the modes and strategic moves considered suitable for entering the Global Rail Asset Management Market? Read the full report: https://www.reportlinker.com/p05993382/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Dublin, Dec. 03, 2020 (GLOBE NEWSWIRE) -- The "Global Embolization Coil Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The embolization coil market is poised to grow by $215.58 million during 2020-2024 progressing at a CAGR of 5% during the forecast period. Our reports on embolization coil market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of aneurysms and availability of favourable reimbursement coverage. The embolization coil market analysis includes application segment and geographic landscape. This study identifies technological advances as one of the prime reasons driving the embolization coil market growth during the next few years. Also, market expansion in emerging economies and implementation of organic and inorganic strategies by market players will lead to sizable demand in the market. This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The embolization coil market report covers the following areas: * Embolization coil market sizing * Embolization coil market forecast * Embolization coil market industry analysisThis robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading embolization coil market vendors that include Balt USA LLC, Boston Scientific Corp., Cook Group Inc., Cardinal Health Inc., Johnson & Johnson, ab medica Deutschland GmbH & Co. KG, Medtronic Plc, Shape Memory Medical Inc., Sirtex Medical Pty Ltd., and Terumo Corp. Also, the embolization coil market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth. Key Topics Covered: 1\. Executive Summary * Market Overview2\. Market Landscape * Market ecosystem * Market characteristics * Value chain analysis3\. Market Sizing * Market definition * Market segment analysis * Market size 2019 * Market outlook: Forecast for 2019 - 20244\. Five Forces Analysis * Five force summary * Bargaining power of buyers * Bargaining power of suppliers * Threat of new entrants * Threat of substitutes * Threat of rivalry * Market condition5\. Market Segmentation by Application * Market segments * Comparison by Application * Neurology - Market size and forecast 2019-2024 * Oncology - Market size and forecast 2019-2024 * Peripheral Vascular disease - Market size and forecast 2019-2024 * Cardiology - Market size and forecast 2019-2024 * Others - Market size and forecast 2019-2024 * Market opportunity by Application6\. Market Segmentation by Deployment * Market segments * Comparison by Deployment * Detachable coil - Market size and forecast 2019-2024 * Pushable coil - Market size and forecast 2019-2024 * Market opportunity by Deployment7\. Customer Landscape 8\. Geographic Landscape * Geographic segmentation * Geographic comparison * North America - Market size and forecast 2019-2024 * Europe - Market size and forecast 2019-2024 * APAC - Market size and forecast 2019-2024 * South America - Market size and forecast 2019-2024 * MEA - Market size and forecast 2019-2024 * Key leading countries * Market opportunity by geography * Market drivers * Market challenges * Market trends9\. Vendor Landscape * Vendor landscape * Landscape disruption10\. Vendor Analysis * Vendors covered * Market positioning of vendors * Balt USA LLC * Boston Scientific Corp. * Cook Group Inc. * Cardinal Health Inc. * Johnson & Johnson * ab medica Deutschland GmbH & Co. KG * Medtronic Plc * Shape Memory Medical Inc. * Sirtex Medical Pty Ltd. * Terumo Corp.11\. Appendix * Scope of the report * Currency conversion rates for US$ * Research methodology * List of abbreviationsFor more information about this report visit https://www.researchandmarkets.com/r/4w9gjtResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Your Social Security income could be 30% lower if you claim early, but you can make up for the lost income in other areas of your budget.
Dashcam footage has captured the moment a truck's heavy load came loose and crushed another vehicle. See how the driver of the crushed vehicle survived.
PRESS RELEASE Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 December 2020) Immunocore (or the “Company”), a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that it will present new clinical results on tebentafusp (IMCgp100) at the European Society of Medical Oncology Immuno-Oncology (ESMO IO) Virtual Congress on the 12th December. These data represent the primary clinical results from a Phase 2 study of tebentafusp in previously treated, metastatic uveal melanoma (mUM) patients.The Phase 2 study investigated the overall response rate (ORR), with secondary objectives being overall survival (OS) and safety in 127 patients who had enrolled after progressing on one or more prior therapies. During the session, Dr. Joseph Sacco, Consultant in Medical Oncology, Clatterbridge Cancer Centre, will present the clinical results from the trial.“In this phase 2 study of previously treated metastatic uveal melanoma, we observed a promising survival that replicates the overall survival benefit we recently reported in our randomized phase 3 study in previously untreated patients,” said David Berman, Head of Research and Development at Immunocore. “TCR bispecifics represent a new frontier in IO which will require matching science to clinical observation. Because the proposed mechanism of action includes redirecting T cells into a solid tumor, the survival benefit in patients treated with tebentafusp showed the potential to extend beyond RECIST-defined response rate to also include immune-related responses.”In this Phase 2 study, the overall RECIST-defined response rate (ORR) was 5%, with 45% of patients achieving stable disease. Among patients with evaluable tumours, 44% had reduction in the sum of target lesions, including demonstration of immune-related responses. Median overall survival (OS) was 16.8 months, with a 12-month OS rate of 62%. The historical 12-month OS rate in previously treated patients is approximately 40%.Patients who developed a rash, a proposed on-target adverse event (AE), within 7 days of starting tebentafusp had a 12-month OS rate of 77% compared to approximately 40% of those who did not develop a rash. Patients with any reduction in the sum of target lesions, including those with immune-related responses, had a 12-month OS rate of 86%.Treatment-related AEs were consistent with the proposed mechanism of action, and were generally manageable and decreased in severity after the first three doses; only 3.7% of patients discontinued treatment due to a related AE and there were no fatal treatment-related AEs.\- Ends -About Immunocore Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated monotherapy activity in a Phase 2 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies, and is currently being studied in an ongoing Phase 3 clinical trial. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, U.K., with offices in Conshohocken, Pennsylvania and Rockville, Maryland in the United States. For more information, please visit www.immunocore.com.About ImmTAC® MoleculesImmunocore’s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognise and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognise intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumours, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumours, regardless of mutational burden or immune infiltration, including immune “cold” low mutation rate tumours. About TebentafuspTebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumour cells. Tebentafusp has been granted Fast Track Designation and orphan drug designation by the FDA in the United States and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. For more information about enrolling tebentafusp clinical trials for metastatic uveal melanoma, please visit ClinicalTrials.gov (NCT03070392).About Uveal MelanomaUveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Metastatic uveal melanoma typically has a poor prognosis and has no currently accepted optimal management or treatment., Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, with approximately 8,000 new patients diagnosed globally each year (1,600-2,000 cases/year in the US).,, Up to 50% of people with uveal melanoma will eventually develop metastatic disease.1,2 When the cancer spreads beyond the eye, only approximately half of patients will survive for one year.For more information, please contact:Immunocore Debra Nielsen, Head of Communications T: +1 (610) 368-8602 E: email@example.com Follow on Twitter: @ImmunocoreConsilium Strategic Communications (corporate and financial) Mary-Jane Elliott/ Chris Welsh/ Sukaina Virji T: +44 (0)203 709 5700 E: Immunocore@consilium-comms.com Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers. 2019;11(7):971. Carvajal, RD, Schwartz, GK, Tezel, T, et al., 2017. Metastatic disease from uveal melanoma: treatment options and future prospects. British Journal of Ophthalmology, 101(1), 38-44. Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous and uveal melanoma specificities. Genes Dev. 2017;31(8):724-743. Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 2013;6(7):1230-1244. About ocular melanoma. Ocular Melanoma Foundation website. www.ocularmelanoma.org/about-om.htm. Accessed September 2019. Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res 2019
Greece extended by a week a nationwide lockdown it imposed in November to contain a surge in coronavirus cases, the country's government spokesman said on Thursday. "The cases are declining but at a slower pace than expected," government spokesman Stelios Petsas said.
When technical problems marred the ballyhooed launch of the Affordable Care Act's website, President Barack Obama turned to Jeff Zients, an economic adviser touted for his managerial skills, to repair Obama's signature policy rollout. Seven years later, Obama's vice president, President-elect Joe Biden, is considering tapping Zients to tackle a far more daunting problem as the incoming administration's coronavirus "czar," according to a Biden ally briefed on his thinking. The prominent position would be similar to the role that Ron Klain, Biden's soon-to-be chief of staff, played for the Obama administration during the Ebola crisis in 2014.
Participation in Series C financing round signifies DENSO’s focus on collaborative development and accelerating innovationSOUTHFIELD, Mich., Dec. 03, 2020 (GLOBE NEWSWIRE) -- DENSO, a leading mobility supplier, today announced it has invested again in mobility platform developer Ridecell as part of the company’s Series C financing round. DENSO first invested in Ridecell, which helps commercial fleets digitally transform their operations, in 2017. DENSO’s investments strengthen ties between the companies and allow each to accelerate advances in connected solutions for mobility providers. These advancements are particularly useful to fleet operators looking for more seamless and efficient ways to manage fleet data, automate workflows and ensure secure vehicle access.“Working with Ridecell and their fleet customers has been invaluable as we advance the development and commercialization of new mobility services,” said Rob Wunsche, director of Mobility Platform Services and New Product Innovation at DENSO. "When DENSO invests in partners, our mission is to leverage each other's strengths to innovate, and with Ridecell, that translates to a powerful set of solutions for fleet owners."Ridecell’s ability to provide data insights and workflow automation for fleets, motor pools and trucking and logistics companies comes at a time when digital solutions are more important than ever. COVID-19 has raised consumer and enterprise rental demand, and increased the need for contactless reservation and entry and drop-off solutions in the shared vehicle market.“The leading fleets in the world were already working on digital transformation,” said Aarjav Trivedi, CEO of Ridecell. “COVID-19 created an urgent need for them to accelerate digital access to their fleets, reduce risk by enabling self-service touch-less monetization across B2B and B2C business models, and reduce costs through automation. For Ridecell, it created opportunities to help many customers and partners quickly meet the shifting consumer and enterprise demand for fleet operations automation and contactless commerce. We are excited to continue that momentum, and welcome our C-round investors to our team as we deliver the premier technology platform for mobility companies and fleet operators in a post-pandemic era.”Despite the challenges posed this year by COVID-19, DENSO remains committed to its Second Founding, the company’s strategy to enrich mobility and meet the evolving needs of its customers. As part of this, DENSO’s collaborative development with partners can help it expand into new mobility areas and build new revenue streams, all while making transportation safer, greener and more efficient for all. DENSO’s investment in Ridecell supports such efforts.In November, DENSO also invested in Lambda:4, a German developer of wireless positioning technologies often used in search and rescue missions, to strengthen its passive digital key.About DENSO DENSO is a $47.6 billion global mobility supplier that develops advanced technology and components for nearly every vehicle make and model on the road today. With manufacturing at its core, DENSO invests in its 200 facilities to produce thermal, powertrain, mobility, electrification, & electronic systems, to create jobs that directly change how the world moves. The company’s 170,000+ employees are paving the way to a mobility future that improves lives, eliminates traffic accidents, and preserves the environment. Globally headquartered in Kariya, Japan, DENSO spent 9.9 percent of its global consolidated sales on research and development in the fiscal year ending March 31, 2020. For more information about global DENSO, visit https://www.denso.com/global.In North America, DENSO is headquartered in Southfield, Michigan, and employs 27,000+ engineers, researchers and skilled workers across 51 sites in the U.S, Canada and Mexico. In the United States alone, DENSO employs 17,700+ employees across 14 states (and the District of Columbia) and 41 sites. In fiscal year ending March 31, 2020, DENSO in North America generated $10.9 billion in consolidated sales. DENSO is committed to advancing diversity and inclusion inside the company and beyond – a principle that brings unique perspectives together, bolsters innovation and pushes DENSO forward. Join us, and craft not only how the world moves, but also your career: densocareers.com. For more information, go to https://www.denso.com/us-ca/en/.About Ridecell Ridecell helps companies build and operate profitable mobility businesses. With the company’s High-yield Mobility™ toolkit of intelligent software, business services, and ecosystem partners, Ridecell customers maximize three key profit drivers: customer experience; fleet utilization; and operational efficiency.Founded in 2009, today Ridecell powers some of the most successful shared mobility services in cities across Europe and North America. These services include Gig Car Share from AAA, ZITY from Ferrovial and Groupe Renault.Ridecell is headquartered in San Francisco, California, with more than 170 employees in offices across the globe.Contact: Andrew Rickerman DENSO International America, Inc. (734) 560-8752 firstname.lastname@example.org
The Continuations aim to Strengthen and Broaden the IPSAN DIEGO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”), announced as a further update to its press release issued November 24, 2020, that it filed for continuation for its 3D microchip and database sharing patents and received a grant date as of December 1, 2020 from the United States Patent and Trademark Office (“USPTO”). The continuation application has been assigned serial number 17102928 by the USPTO. The goal of the continuation application is to strengthen and broaden the protection of the intellectual property.The patent seeks to cover new silicon manufacturing structure and orientation, with the stated designed of providing more capabilities and lower power consumption with reduced cost. The goal of the new manufacturing architecture is to enable larger designs within smaller areas and significantly increases the silicon yield to enhance smaller nodes like 5nm, 3nm and below. The invention is defined to support analog, RF, digital, MIXED and MEMS IC's design styles. The mobile database management and sharing patent is designed to enable secured communication protocol and to produce faster, more secured processing of database objects throughout networks. The technology covered by the patent is aimed to enable sharing and exchange of vast amounts of data using segmentation oriented, secured techniques. The patent covers database communication within conventional networks like cellular, radio, WLAN, LAN, the Internet and private protocols including internal communication inside integrated circuits units. The patent also covers radio based networks to protect IoT and mobile technologies. By its working definition, the goal of the system is to offer another advanced security top-layer to protect the network's security and potentially boost its speed exponentially. Forward-Looking StatementsCertain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.Contact: Dr. Danny Rittman, CTO email@example.com
President Donald Trump's administration is pushing to finalize new immigration restrictions before his term ends in January, according to three senior homeland security officials, a last-gasp effort in a policy area that was a central focus during his four years in office. The moves come even as Democratic President-elect Joe Biden has pledged to rescind many of Trump's immigration policies. By finalizing rules that have just been proposed, or issuing last-minute orders, the administration could slow down Biden's efforts to undo many of Trump's signature measures that have made it harder for immigrants to enter and settle in the United States.
Press Release Nokia and Metrotel deploy software-defined fiber network for open access in Argentina * Metrotel uses Nokia’s Altiplano cloud platform and Cloud Acceleration Professional Services to build a state-of-the-art shared fiber infrastructure, based on passive optical network (PON) technology * The deployment helps meet Argentina’s broadband needs by providing cost-effective, high-speed fiber optic connectivity and related services to more than 40,000 users * Metrotel will initially focus on enterprise customers, using the new network’s slicing capability to optimize services by market segment * Metrotel will then use the new infrastructure to fulfil its strategic goal of becoming a broadband wholesaler, including in the residential market, and to support 5G mobile backhaul (MBH) services3 December 2020 Espoo, Finland - Nokia today announced it will deploy the Altiplano cloud platform for fiber access in Metrotel’s network. This deployment enables Metrotel to deliver high-speed broadband and related services to users across Argentina. Metrotel has already built 4000 km of fiber networks, spanning Greater Buenos Aires, Rosario, Córdoba, Mendoza and Neuquén. By deploying Nokia Lightspan fiber access nodes, Metrotel will be able to provide cheaper and faster connectivity to 40,000 customers across these regions.Metrotel will use the solution to support corporate customers in sectors including financial services, media, hospitality and government, whose needs call for a cost-effective and fully serviced fiber optic network. Flexible control and easy integration allow Metrotel to tailor its offering to individual market segments. Nokia’s high-capacity Lightspan FX access nodes provide the required scale.Metrotel aims to become a broadband wholesaler, providing high-speed connectivity and comprehensive support services to virtual network operators who serve the residential market. The network will also support 5G mobile backhaul services, helping to accelerate rollout of 5G capabilities across Argentina.To build the new network infrastructure, Metrotel selected Nokia’s cloud-native Altiplano platform for the flexibility it offers - it can easily be integrated with existing IT and operations support systems. The intent-based Altiplano Access Controller will enable Metrotel to vastly improve its network customization and management, through open programmable interfaces and closed-loop automated operations. Nokia Cloud Acceleration Professional Services provide system integration services to integrate Altiplano cloud platform in Metrotel cloud infrastructure. Altiplano customization services provide customer specific intents to support Metrotel’s requirements for their business customers.Germán Garay, CTO at Metrotel, said: “This deployment allows us to increase the degree of integration, simplification and abstraction of our services to support our customers, providing continuous network optimization and long-term network services built around their needs. We chose Nokia for their comprehensive but also highly dynamic solution; new and scalable PON technologies; software oriented around shorter innovation cycles; and an architecture based on microservices, automation and virtualization. This makes the best use of both new and existing infrastructure and gives our customers the best possible value.”Sandra Motley, President of Fixed Networks at Nokia, said: “Nokia’s Altiplano cloud platform and fiber access solutions will enable Metrotel to deliver high-speed broadband and related services to its users across Argentina. Our Cloud Acceleration portfolio of professional services helps Metrotel deploy and operate SDN-enabled broadband networks and use cases quickly and efficiently. Our goal is to simplify Metrotel’s evolution to cloud and software-defined networking, leveraging our SDAN Integration and Migration Operation Centers and DevOps automation.”Resources Webpage : Cloud Acceleration Services Webpage : Altiplano Access Controller Webpage : Take your broadband to the cloudAbout Nokia We create the technology to connect the world. Only Nokia offers a comprehensive portfolio of network equipment, software, services and licensing opportunities across the globe. With our commitment to innovation, driven by the award-winning Nokia Bell Labs, we are a leader in the development and deployment of 5G networks.Our communications service provider customers support more than 6.4 billion subscriptions with our radio networks, and our enterprise customers have deployed over 1,300 industrial networks worldwide. Adhering to the highest ethical standards, we transform how people live, work and communicate. For our latest updates, please visit us online www.nokia.com and follow us on Twitter @nokiaMedia Inquiries:Nokia Communications Phone: +358 10 448 4900 Email: firstname.lastname@example.org